Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | REN | P00797 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2244333 | 0.90 | KMT2A (0.35) | ALDH1A1SMN1; SMN2KMT2APOLBGAA | |
| SCHEMBL12353088 | 0.90 | REN (0.43) | ALDH1A1SMN1; SMN2KMT2AHTTPOLB | |
| SCHEMBL12353060 | 0.89 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2KMT2AHTTPOLB | |
| SCHEMBL12353056 | 0.89 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2KMT2AHTTPOLB | |
| SCHEMBL12353221 | 0.88 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2KMT2AHTTPOLB | |
| SCHEMBL12352835 | 0.88 | REN (0.45) | ALDH1A1SMN1; SMN2KMT2AHTTPOLB | |
| SCHEMBL7602512 | 0.88 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2KMT2AHTTPOLB | |
| SCHEMBL12353082 | 0.87 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2KMT2AHTTPOLB | |
| SCHEMBL12353217 | 0.87 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2KMT2AHTTPOLB | |
| SCHEMBL12353081 | 0.87 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2KMT2AHTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389511-B2 | Bicyclic heterocyclic derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-03-05 | — | — | US | disclosed |
| US-20110190278-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO. | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190278-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | REN, AGTR1, AGTR2 | ALDH1A1 288/4885SMN1; SMN2 4394/4885KMT2A 1812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.